Answers are grounded in this paper and cite their sources.
Exploratory trial analysis reveals low-dose capecitabine improves disease-free survival in triple-negative breast cancer, highlighting the impact of standard adjuvant chemotherapy dosing.
Purpose: Results from studies of extended capecitabine after the standard adjuvant chemotherapy in early stage triple-negative breast cancer (TNBC) were inconsistent, and only low-dose capecitabine from the SYSUCC-001 trial improved disease-free survival (DFS).Adjustment of the conventional adjuvant chemotherapy doses affect the prognosis and may affect the efficacy of subsequent
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: